Welcome to the weekend everybody. We hope you had a good trading week. The market certainly did what it could to do to make things good for you, spurred by some dovish comments from the Fed Chair-elect Janet Yellen. I could take about how that prod took the market a little higher on Friday, pushing (although straining to do so) the indices into new-high territory. You know that though? I've pretty much beat that horse to death with you guys already, and I'm not going to do it again. When whatever's going to happen finally happens - and we'll know it when we see it - we can talk about it then. Until then, there's not much point in going through the same exercise. So what do I want to talk about? Something that made my trading success infinitely better, pretty much immediately. Get More Out of the Market It occurred to me a couple of days ago that I recommend the SmallCap Network Elite Opportunity to you guys all the time, but unless you've actually seen it firsthand (as a subscriber, or at least as a trial user), my words just don't do it justice. So, since we have time today, I wanted to show you a handful of snippets subscribers to the SCN EO newsletter have received in their inbox, just to you can get a feel for how valuable this service really is. Now, before anybody gets any ideas about poaching some of the recent picks and market analysis that's exclusive to current SmallCap Network Elite Opportunity subscribers, forget about it. John Monroe has made it crystal clear to me that he'll never put SCN EO members at a disadvantage by sharing parts of the newsletter that are still timely and relevant, so I'm not going to be the one to goof up that promise. I'll only be sharing with you some older stuff that makes it clear what the newsletter is, and how it can make you a better trader. First and foremost, you have to understand that a subscription to the SCN EO isn't just a access to a stock-picking portfolio. John Monroe and his analytical team are just about the best there is when it comes to making short-term and long-term market calls. It's always good stuff too, and the kind of analysis you're not going to get anywhere else. Check this out from the September 27th newsletter: Getting back to some important index analysis, based on what we're seeing, it looks as if we have a pretty decent idea of where the S&P may be headed on an extremely short-term basis, which is always fairly difficult to dissect, however, this same chart I referenced above also includes some very key technical points I want to comment on here today. I've included some key retracement levels off of both the June and August bottoms and back off last week's top. I've also included what I believe will end up being a fairly important trend line going into next week. As you can see above, I've circled a key confluence area based on this retracement lines, which puts the S&P somewhere between 1,663 and 1,666. Coincidently, or maybe not, the trend line runs right through that same level, suggesting that could be where the S&P may want to pause and reverse on an extremely short-term basis, which would likely end up being enough of a reversal for at least a short-term leveraged ETF trade to the long side, before it's all said and done. On a bit more of an extended timeframe, if you remember back when these markets were selling off in early August, I kept pointing to 1,600 on the S&P as being a level the index may likely want to gravitate toward before we'd be convinced it was a deep enough selloff to suggest getting bullishly aggressive again, however, the index only got to about 1,626 before reversing itself and moving higher throughout most of September. Well, guess what? Now that the S&P made a new high at 1,729 last week, a full and complete 3/8 retracement of this whole rally that started on day one of this year, now sits at roughly 1,600. See how efficient these markets can be? It's possible we still may end up seeing that 1,600 level before it's all said and done. And, like I said above, as painful as that may be on a short-term basis, it would absolutely be an excellent technical event to see the markets get down to that level. The bottom line is this. Let's not get too aggressive putting money to work on the bullish side of the markets right now. Let's remain patient and opportunistic. You don't have to be hyperactive to beat the averages on a year-to-year basis. That's a huge misconception. There are times when it's simply better to do nothing and there are times to get aggressive. You see what I mean? There's a plan and framework in place... a short-term and a long-term one. John Monroe get specific too, naming target levels and likely reversal points. It's such a breath of fresh air to see someone not talk broadly and philosophically about the market (which I admit I'm guilty of), but rather, give traders specific spots where decisions should be made. The SmallCap Network Elite Opportunity service isn't just a market-handicapping tool though. As good as these guys are at figuring out where the broad market is going to ebb and flow, they're even better at picking stocks. Even better than that, they're the absolute best at explaining why they like a particular stock well enough to buy it. Check out this recommendation/explanation the SCN EO team posted when they picked BioTelemetry (BEAT) back on June 12th, when the company was still known as CardioNet. Today's new idea, CardioNet, Inc. (BEAT), appears to have met the preferred criteria on both fronts. I must admit, I've been watching and wanting to put this idea out there for a few weeks now and have been waiting to see what the broader markets wanted to do first. Big mistake. The Company announced a major catalyst after the close Monday that was a big game changer for the Company and its stock. However, rather than cry over spilt milk, I'm going to simply use Monday's announcement as further confirmation this Company is on a very good growth curve. I'll get to this major corporate development in a bit but first, CardioNet is the leading provider of ambulatory, continuous, real-time outpatient management solutions for monitoring relevant and timely clinical information regarding an individual's health. CardioNet's initial efforts are focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, with a solution that it markets as Mobile Cardiac Outpatient TelemetryTM (MCOTTM). If you want to learn more about the Company, you can go to: http://www.cardionet.com. There's a lot of very exciting technology taking place in the healthcare space, which in general, I believe offers tremendous growth going forward with the single largest generation in recent history, the baby boomers, now entering their golden years. Some of this technology is focused on outpatient care and mobile platforms to help monitor and facilitate critical healthcare needs that have only previously been available to inpatient services. This new technology, in my opinion, is going to be extremely disruptive in the years ahead and offers the right companies a tremendous amount of growth opportunity. Imagine this, patients or pre-diagnosed individuals showing signs of heart rhythm disorders can now be monitored remotely and wirelessly for early signs of cardiac arrhythmias before it's too late. Couple this disruptive technology with the largest generation now aging into those years of concern and we have a real potential winner on our hands. Monday, after the close, the Company confirmed their position in the space. With CardioNet being a leader in wireless medical technology, the Company announced they have entered into a three-year National Provider Agreement with UnitedHealthcare Insurance Company, covering all of CardioNet's monitoring modalities, including Mobile Cardiac Outpatient Telemetry (MCOTTM). The Agreement is effective July 1, 2013 and applies to all UnitedHealthcare affiliated entities, including managed Medicare and managed Medicaid plans. UnitedHealthcare provides coverage to more than 70 million members in the United States. Rather than include a daily chart here, which actually doesn't mean much to us, I've included a monthly chart dating back to BEAT's early beginnings as a public company. You'll notice when BEAT first went public, the stock traded well north of $30 per share. I guess when it's all said and done, even though we missed yesterday's move, the stock is still a far cry from its 2008 high. This is pretty typical with the majority of IPO's. Usually, IPO's get overly hyped, reality settles in suggesting a company's growth will take time and those early participants often get taken to the woodshed. All things considered, we like our entry into BEAT around current level. From a fundamental perspective, the Company has over $18M in cash and no debt (trading at less than ten times cash), a key aspect of a company's financials you've probably noticed we're big fans of. I always have a hard time investing in ideas with a ton of debt. Shares of BEAT are currently trading at just over a mere one times revenue. Excellent for a small cap. Although the Company hasn't turned the net profit corner yet, I would suspect their recent announcement with UnitedHealthcare will do wonders for that key fundamental component. Let me be clear here, although this could turn into an excellent short-term trader, that's not our goal with BEAT. We're suggesting BEAT as a long-term investment story. And, if you've been with us for any substantial amount of time, you know we only suggest allocating to any small cap idea what you might be willing to lose. Greed should not be an emotion when considering what to allocate to any stock. As to when and how you decide to jump into BEAT, you can either get in now, tuck it away and forget about it unless something glaring surfaces, or you could look to enter on weakness once the initial euphoria wears off. It's up to you. Whatever you decide to do, be prepared for a tremendous amount of volatility. When it comes to chart technicals on low priced ideas that have recently broken out, like BEAT, you can often throw the charts right out the window, as much of the way it will trade going forward will be dependent on when and where large funds decide to get in or out and how the market makers decide to shake out weak hands in the process. With that being said, we're going to set our initial target in BEAT at $12.44 per share, which represents a very long-term 3/8 retracement level from its 2009 high to its all-time low. We'll set our suggested stop loss at Monday's low of $3.20 per share. Again, this is a very long-term idea we want to give plenty of breathing room, so only allocate what you're potentially willing to lose about 35% on. If our analysis proves correct and management continues to deliver, we could be looking at triple digit gains and a double bagger before it's all said and done. OK, I know that was a lot to read through, but probably worth it for SmallCap Network Elite Opportunity subscribers at the time. The trade is now up 141% since it was bought a few months ago. Now, while the whole point of showing you all this text was to illustrate how the SCN EO can teach you as much as help you make more money, I know I still haven't done the newsletter its proper justice. The only way to really know just how valuable the SmallCap Network Elite Opportunity to you is to either subscribe, or take the two-week trial offer. I suggest the two-week trial because, well, it's free, but that's still enough time to get a feel for just how good John Monroe and his team are. Or, you can keep doing what you've been doing, and keep getting what you've been getting. Your call. If you're really interested in getting more out of the market, however, I recommend getting the two-week free trial as soon as possible, as I don't know how much longer the trial offer will be available. Here's how to get the free trial . Or, copy and paste the following link in your browser: http://www.smallcapnetwork.com/?vmpd_ckstr[click_track]=SCN+Newsletter&vmpd_ckstr_redirect=/pages/SCNEO/v1/